Document:

NEUBASE THERAPEUTICS, INC. S-8

 

 Exhibit
4.6

 

NEUBASE
THERAPEUTICS, INC.

2019
STOCK INCENTIVE PLAN

STOCK
OPTION AGREEMENT

NOTICE
OF STOCK OPTION GRANT 

Unless
otherwise defined herein, the terms used in this Stock Option Agreement, including the Notice of Stock Option Grant (the “Notice
of Grant”), the Terms and Conditions of Stock Option Grant, and the addendum (if any) and the exhibits attached
thereto (collectively, this “Award Agreement”) shall have the meanings given to such terms in the NeuBase
Therapeutics, Inc. 2019 Stock Incentive Plan (as may be amended or restated from time to time, the “Plan”).

	 	 	 
	Name
    (“Participant”):	 	[•]
	 	 
	Address:	 	[•]
	 	 	[•]

The
undersigned Participant has been granted an Option (the “Option”) to purchase Common Stock of NeuBase
Therapeutics, Inc. (the “Company”), subject to the terms and conditions of the Plan and this Award Agreement,
as follows:

	Grant
    Number:	 	[•]

    

    
	 	 	 
	Date
    of Grant:	 	[•]
	 	 
	Vesting
    Commencement Date:	 	[•]
	 	 
	Number
    of shares of Common Stock (“Shares”) Granted:	 	[•]
	 	 
	Exercise
    Price per Share:	 	$[•]
	 	 
	Total
    Exercise Price:	 	$[•]
	 	 
	Type
    of Option:	 	        
    Incentive Stock Option
	 	 
	 	 	        
    Nonqualified Stock Option
	 	 
	Term/Expiration
    Date:	 	[•]

Vesting
Schedule:

Subject
to the provisions contained in the Plan or set forth below, the Option will be exercisable, in whole or in part, in accordance
with the following schedule:

[Note: Insert Vesting Schedule, e.g.: Twenty-five percent (25%) of the Shares subject to the Option shall vest on
the one (1) year anniversary of the Vesting Commencement Date, and, following the one (1) year anniversary of the Vesting
Commencement Date, the remaining seventy-five percent (75%) of the Shares subject to the Option shall vest in equal monthly installments
over a period of the next three (3) years on the same day of the month as the Vesting Commencement Date (and if there is no corresponding
day, on the last day of the corresponding month in which such vesting would have occurred), subject to Participant continuing
to be an eligible service provider under Article IV of the Plan through and including each such date.]

     

     

    

Termination
Period:

If
Participant incurs a Termination Date for any reason other than death or Cause, the Option, to the extent it was exercisable as
of the Termination Date, will be exercisable for (i) three (3) months after the Termination Date of the Participant or (ii)
until the Term/Expiration Date, whichever period is shorter. If such termination is due to Participant’s death, the Option
will be exercisable for (i) twelve (12) months after the Termination Date of the Participant or (ii) until the Term/Expiration
Date, whichever period is shorter. Notwithstanding any other provision of this Award Agreement, all rights to the Option will
be immediately discontinued and forfeited, and the Company shall not have any further obligation hereunder to the Participant
with respect to the Option and the Option will not be exercisable (whether or not previously exercisable) or become vested or
payable on and after the time the Participant is discharged from employment or service with the Company or any Affiliate for Cause.
Notwithstanding the foregoing, the Option may in no event be exercised after the Term/Expiration Date as provided above and may
be subject to earlier termination as provided in Section 11.05 and Section 12.01 of the Plan. Participant is responsible for keeping
track of these exercise periods following the date Participant ceases to be an eligible service provider under Article IV of the
Plan for any reason. The Company will not provide further notice of such periods. 

Participant
acknowledges receipt of a copy of the Plan and the prospectus describing the Plan and represents that he or she is familiar with
the terms and provisions thereof, and hereby accepts this Award Agreement subject to all of the terms and provisions thereof.
Participant has reviewed the Plan and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel,
accountants and advisors prior to executing this Award Agreement and fully understands all provisions of the Plan and this Award
Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee
upon any questions arising under the Plan or this Award Agreement. Participant further agrees to notify the Company upon any change
in the residence address indicated below.

     

     

    

  

	 	 	 	 	 
	PARTICIPANT	 	 	 	NEUBASE
    THERAPEUTICS, INC.
	 	 	 
	 

         
	 	 	 	 

         

	Signature	 	 	 	By
	 	 	 
	«Name»	 	 	 	 
	Print
    Name	 	 	 	Print
    Name
	 	 	 
	 	 	 	 	 

         

	 	 	 	 	Title

Participant’s
Address:

	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

     

     

    

NEUBASE
THERAPEUTICS, INC. 

2019
STOCK INCENTIVE PLAN

STOCK
OPTION AGREEMENT

TERMS
AND CONDITIONS OF STOCK OPTION GRANT 

1.

Grant
of Option. The Company hereby grants to the individual (“Participant”) named in the Notice of Stock
Option Grant of this Award Agreement (the “Notice of Grant”) under the Plan an option (the “Option”)
to purchase the number of Shares, as set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice
of Grant (the “Exercise Price”), subject to all of the terms and conditions in this Award Agreement
and the Plan, which is incorporated herein by reference. Subject to Article XVII of the Plan, in the event of a conflict between
the terms and conditions of the Plan and the terms and conditions of this Award Agreement, the terms and conditions of the Plan
shall prevail in all respects. 

(a)

For U.S. taxpayers, the Option will be designated as either an Incentive Stock Option (“ISO”) or a Nonqualified
Stock Option (“NSO”). If designated in the Notice of Grant as an ISO, the Option is intended to qualify
as an ISO under Section 422 of the U.S. Internal Revenue Code of 1986, as amended (the “Code”).
However, if the Option is intended to be an ISO, to the extent that it exceeds the $100,000 rule of Section 422(d) of the
Code it will be treated as an NSO. Further, if for any reason the Option (or portion thereof) will not qualify as an ISO, then,
to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the Plan. In
no event will the Committee, the Company, any “parent corporation,” whether now or hereafter existing, as defined
in Code Section 424(e) (“Parent”), or any “subsidiary corporation,” whether now or hereafter
existing, as defined in Code Section 424(f) (“Subsidiary”) or any of their respective employees or directors
have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO.

(b)

For non-U.S. taxpayers, the Option will be an NSO. 

2.

Vesting Schedule. Except as provided in Section 3 hereof, the Option awarded by this Award Agreement will vest in
accordance with the vesting schedule set forth in the Notice of Grant, subject to Participant continuing to be an eligible service
provider under Article IV of the Plan through each applicable vesting date. 

3.

Committee Discretion. The Committee, in its sole and absolute discretion, may accelerate the vesting of the balance, or
some lesser portion of the balance, of the unvested Option at any time, subject to the terms of the Plan. If so accelerated, such
Option will be considered as having vested as of the date specified by the Committee. 

4.

Exercise
of Option. 

(a)

Right
to Exercise. The Option may be exercised only with respect to vested Shares and only within the term set out in the Notice
of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Award Agreement. Notwithstanding
any other provision of this Award Agreement, all rights to the Option will be immediately discontinued and forfeited, and the
Company shall not have any further obligation hereunder to the Participant with respect to the Option and the Option will not
be exercisable (whether or not previously exercisable) or become vested or payable on and after the time the Participant is discharged
from employment or service with the Company or any Affiliate for Cause.

(b)

Method
of Exercise. The Option is exercisable by delivery of an exercise notice (the “Exercise Notice”)
in the form attached hereto as Exhibit A or in a manner and pursuant to such
procedures as the Committee may determine, which will state the election to exercise the Option, the number of Shares in respect
of which the Option is being exercised (the “Exercised Shares”), and such other representations and
agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice will be completed and
executed by Participant and delivered to the Company. The Exercise Notice will be accompanied by payment of the aggregate Exercise
Price as to all Exercised Shares together with any Tax Obligations (as defined in Section 7(a) below). The Option will be
deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise
Price. 

     

     

    

5.

Method
of Payment. Payment of the aggregate Exercise Price will be by any of the following, or a combination thereof, at the election
of Participant: 

(a)

cash; 

(b)

check; 

(c)

consideration received by the Company under a broker-assisted (or other) cashless exercise program implemented by the Company
in connection with the Plan; 

(d)

subject to the sole and absolute discretion of the Committee, if Participant is a U.S. employee, surrender of other Shares which
have a Fair Market Value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares; provided that
accepting such Shares will not result in any adverse financial accounting consequences to the Company, as the Committee determines
in its sole discretion (to the extent not prohibited by the Committee, this shall include the ability to tender Shares to exercise
the Option and then to use the Shares received upon exercise to exercise the Option with respect to additional Shares); 

(e)

if the Option is a non-ISO, subject to the consent of the Company at the time of exercise, by a “net exercise” arrangement
pursuant to which the Company will reduce the number of Shares issued upon exercise of the Option by the largest whole number
of shares with a Fair Market Value that does not exceed the aggregate Exercise Price; provided that Participant must pay
any remaining balance of the aggregate Exercise Price not satisfied by the “net exercise” in cash or other permitted
form of payment. Shares will no longer be outstanding under the Option and will not be exercisable thereafter if such Shares (i)
are used to pay the Exercise Price pursuant to the “net exercise,” (ii) are delivered to Participant as a result of
such exercise, and (iii) are withheld to satisfy Participant’s tax withholding obligations; or

(f)

any other form of legal consideration that may be acceptable to the Committee and specified in this Award Agreement.

6.

Tax
Consequences. Participant has reviewed with his or her own tax advisors the U.S. federal, state, local and foreign tax consequences
of this investment and the transactions contemplated by this Award Agreement. With respect to such matters, Participant relies
solely on such advisors and not on any statements or representations of the Company or any of its agents, written or oral. Participant
understands that Participant (and not the Company) shall be responsible for Participant’s own tax liability that may arise
as a result of this investment or the transactions contemplated by this Award Agreement. 

7.

Tax
Obligations. 

(a)

Participant
acknowledges that, regardless of any action taken by the Company or, if different, Participant’s employer (the
“Employer”) or Parent or Subsidiary to which Participant is providing services (together, the
Company, the Employer and/or Parent or Subsidiary to which Participant is providing services, the “Service
Recipient”), the ultimate liability for any tax and/or social insurance liability obligations and requirements
in connection with the Option, including, without limitation, (i) all federal, state and local taxes (including
Participant’s Federal Insurance Contributions Act (FICA) obligation) that are required to be withheld by the Company or
the Service Recipient or other payment of tax-related items related to Participant’s participation in the Plan and
legally applicable to Participant, (ii) Participant’s and, to the extent required by the Company (or Service
Recipient), the Company’s (or Service Recipient’s) fringe benefit tax liability, if any, associated with the
grant, vesting or exercise of the Option or sale of Shares, and (iii) any other Company (or Service Recipient) taxes the
responsibility for which Participant has, or has agreed to bear, with respect to the Option (or exercise thereof or
issuance of Shares thereunder) (collectively, the “Tax Obligations”), is and remains
Participant’s responsibility and may exceed the amount actually withheld by the Company or the Service Recipient.
Participant further acknowledges that the Company and/or the Service Recipient: (A) make no representations or undertakings
regarding the treatment of any Tax Obligations in connection with any aspect of the Option, including, but not limited to,
the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the
receipt of any dividends or other distributions, and (B) do not commit to and are under no obligation to structure the
terms of the grant or any aspect of the Option to reduce or eliminate Participant’s liability for Tax
Obligations or achieve any particular tax result. Further, if Participant is subject to Tax Obligations in more than one (1)
jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable,
Participant acknowledges that the Company and/or the Service Recipient (or former employer, as applicable) may be required to
withhold or account for Tax Obligations in more than one (1) jurisdiction. If Participant fails to make
satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable
event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.

     

     

    

(b)

Tax
Withholding. When the Option is exercised, Participant generally will recognize immediate U.S. taxable income if Participant
is a U.S. taxpayer and the Option is an NSO or an alternative minimum tax income adjustment item if Participant is a U.S. taxpayer
and the Option is an ISO. If Participant is a non-U.S. taxpayer, Participant will be subject to applicable taxes in his or her
jurisdiction. Pursuant to such procedures as the Committee may specify from time-to-time, the Company and/or the Service Recipient
shall withhold the minimum amount required to be withheld for the payment of Tax Obligations or such greater amount as permitted
by the Committee and requested in writing by the Participant, up to the maximum statutory rate under applicable laws that could
be applicable to Participant, if such greater amount would not result in adverse financial accounting consequences to the Company,
as determined by the Company in its sole and absolute discretion. The Committee, in its sole and absolute discretion and pursuant
to such procedures as it may specify from time-to-time, may permit Participant to satisfy such Tax Obligations, in whole or in
part (without limitation), if permissible by applicable local law, by (i) paying cash, (ii) electing to have the Company
withhold otherwise deliverable Shares having a Fair Market Value equal to the minimum amount required to be withheld to meet the
withholding requirement for such Tax Obligations (or such greater amount as permitted by the Committee and requested in writing
by the Participant, up to the maximum statutory rate under applicable laws that could be applicable to Participant, if such greater
amount would not result in adverse financial accounting consequences to the Company, as determined by the Company in its sole
and absolute discretion), (iii) withholding the amount of such Tax Obligations from Participant’s wages or other cash
compensation paid to Participant by the Company and/or the Service Recipient, (iv) delivering to the Company already vested
and owned Shares having a Fair Market Value equal to the minimum amount required to be withheld to meet the withholding requirement
for such Tax Obligations (or such greater amount as permitted by the Committee and requested in writing by the Participant, up
to the maximum statutory rate under applicable laws that could be applicable to Participant, if such greater amount would not
result in adverse financial accounting consequences to the Company, as determined by the Company in its sole and absolute discretion),
or (v) remitting through a broker-assisted (or other) cashless exercise program implemented by the Company equal to the minimum
amount required to be withheld to meet the withholding requirement for such Tax Obligations (or such greater amount as permitted
by the Committee and requested in writing by the Participant, up to the maximum statutory rate under applicable laws that could
be applicable to Participant, if such greater amount would not result in adverse financial accounting consequences to the Company,
as determined by the Company in its sole and absolute discretion), or (vi) through any combination of the foregoing.

To
the extent determined appropriate by the Committee in its sole and absolute discretion, the Company will have the right (but not
the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant and, until
determined otherwise by the Company, this will be the method by which such Tax Obligations are satisfied. Further, if Participant
is subject to tax in more than one (1) jurisdiction between the Date of Grant and a date of any relevant taxable or tax withholding
event, as applicable, Participant acknowledges and agrees that the Company and/or the Service Recipient (and/or former employer,
as applicable) may be required to withhold or account for tax in more than one (1) jurisdiction. If Participant fails to make
satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the Option exercise, Participant
acknowledges and agrees that the Company may refuse to honor the exercise and refuse to deliver the Shares if such Tax Obligations
are not delivered at the time of exercise.

(c)

Notice
of Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if Participant sells
or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years
after the Date of Grant, or (ii) the date one (1) year after the date of exercise, Participant will immediately notify
the Secretary of the Company in writing of such disposition. Participant agrees that Participant may be subject to income tax
withholding by the Company and/or the Service Recipient on the compensation income recognized by Participant as a result of such
sale. 

     

     

    

(d)

Code
Section 409A. For U.S. taxpayers, under Section 409A of the Code, and any final Treasury Regulations and Internal
Revenue Service guidance thereunder, as each may be amended from time-to-time (“Code Section 409A”),
a stock right (such as the Option) that was granted with a per share exercise price that is determined by the Internal Revenue
Service (the “IRS”) to be less than the fair market value of an underlying share on the date of grant
(a “Discount Option”) may be considered “deferred compensation.” A Discount Option may result
in (i) income recognition by Participant prior to the exercise of the option, (ii) an additional twenty percent (20%) U.S.
federal income tax, and (iii) potential penalty and interest charges. The Discount Option may also result in additional state
income, penalty and interest charges to Participant. Participant acknowledges that the Company cannot and has not guaranteed that
the IRS will agree that the Exercise Price of the Option equals or exceeds the Fair Market Value of a Share on the Date of Grant
in a later examination. Participant agrees that if the IRS determines that the Option was granted with an Exercise Price that
was less than the Fair Market Value of a Share on the Date of Grant, Participant shall be solely responsible for Participant’s
costs related to such a determination. 

8.

Rights as Stockholder. Neither Participant nor any person claiming under or through Participant will have any of the rights
or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing
such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents
or registrars, and delivered to Participant (including through electronic delivery to a brokerage account). After such issuance,
recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares
and receipt of dividends and distributions on such Shares. 

9.

No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE
HEREOF IS EARNED ONLY BY CONTINUING AS AN ELIGIBLE SERVICE PROVIDER UNDER ARTICLE IV OF THE PLAN, WHICH UNLESS PROVIDED OTHERWISE
UNDER APPLICABLE LAW IS AT THE WILL OF THE COMPANY (OR THE SERVICE RECIPIENT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED
THE OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AWARD AGREEMENT, THE TRANSACTIONS
CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED
ENGAGEMENT AS AN ELIGIBLE SERVICE PROVIDER UNDER ARTICLE IV OF THE PLAN FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND
SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE SERVICE RECIPIENT) TO TERMINATE
PARTICIPANT’S RELATIONSHIP AS AN ELIGIBLE SERVICE PROVIDER UNDER ARTICLE IV OF THE PLAN, SUBJECT TO APPLICABLE LAW, WHICH
TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE. 

10.

Nature
of Grant. In accepting the Option, Participant acknowledges, understands and agrees that: 

(a)

the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants
of options, or benefits in lieu of options, even if options have been granted in the past;

(b)

all decisions with respect to future option or other grants, if any, will be at the sole and absolute discretion of the Company;

(c)

Participant is voluntarily participating in the Plan;

(d)

the Option and any Shares acquired under the Plan are extraordinary items that do not constitute regular compensation for services
rendered to the Company or the Service Recipient, and are outside the scope of Participant’s employment agreement, offer
letter, consulting agreement or similar agreement, if any;

(e)

the Option and any Shares acquired under the Plan, and the income and value of same, are not intended to replace any pension rights
or compensation;

     

     

    

(f)

the Option and any Shares acquired under the Plan and the income and value of same, are not part of normal or expected compensation
for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses,
long-service awards, pension, retirement, welfare benefits or similar payments; 

(g)

the future value of the Shares underlying the Option is unknown, indeterminable and cannot be predicted with certainty; 

(h)

if the underlying Shares do not increase in value, the Option will have no value; 

(i)

if Participant exercises the Option and acquires Shares, the value of such Shares may increase or decrease in value, even below
the Exercise Price; 

(j)

for purposes of the Option, Participant’s status as an eligible service provider under Article IV of the Plan will be considered
terminated as of the Termination Date (regardless of the reason for such termination and whether or not later found to be invalid
or in breach of employment laws in the jurisdiction where Participant is an eligible service provider under Article IV of the
Plan or the terms of Participant’s employment or service agreement, if any), and unless otherwise expressly provided in
this Award Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Committee,
(i) Participant’s right to vest in the Option under the Plan, if any, will terminate as of such Termination Date and
will not be extended by any notice period (e.g., Participant’s period of service would not include any contractual
notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction
where Participant is an eligible service provider under Article IV of the Plan or the terms of Participant’s employment
or service agreement, if any, unless Participant is providing bona fide services during such time); and (ii) the period (if
any) during which Participant may exercise the Option will commence on such Termination Date and will not be extended by any notice
period mandated under employment laws in the jurisdiction where Participant is employed or terms of Participant’s engagement
agreement, if any; the Committee shall have the sole and absolute discretion to determine when Participant is no longer actively
providing services for purposes of the Option grant (including whether Participant may still be considered to be providing services
while on a leave of absence and consistent with local law); 

(k)

unless otherwise provided in the Plan or by the Company in its sole and absolute discretion, the Option and the benefits evidenced
by this Award Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another
company nor to be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares;
and 

(l)

the following provisions apply only if Participant is providing services outside the United States: 

(i)

the Option and the Shares subject to the Option are not part of normal or expected compensation or salary for any purpose;

(ii)

Participant acknowledges and agrees that none of the Company, the Service Recipient, or any Parent or Subsidiary shall be liable
for any foreign exchange rate fluctuation between Participant’s local currency and the United States Dollar that may affect
the value of the Option or of any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of
any Shares acquired upon exercise; and

(iii)

no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from the termination of
Participant’s status as an eligible service provider under Article IV of the Plan (for any reason whatsoever, whether or
not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is an eligible service provider
under Article IV of the Plan or the terms of Participant’s employment or service agreement, if any), and in consideration
of the grant of the Option to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any
claim against the Company, any Parent, any Subsidiary or the Service Recipient, waives his or her ability, if any, to bring any
such claim, and releases the Company, any Parent or Subsidiary and the Service Recipient from any such claim; if, notwithstanding
the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant
shall be deemed
irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal
or withdrawal of such claim.

     

     

    

11.

No
Advice Regarding Grant. The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations
regarding Participant’s participation in the Plan, or Participant’s acquisition or sale of the underlying Shares.
Participant is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation
in the Plan before taking any action related to the Plan. 

12.

Data
Privacy. Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or
other form, of Participant’s personal data as described in this Award Agreement and any other Option grant materials by
and among, as applicable, the Employer or other Service Recipient, the Company, any Parent, or any Subsidiary for the exclusive
purpose of implementing, administering and managing Participant’s participation in the Plan.

Participant
understands that the Company and the Service Recipient may hold certain personal information about Participant, including, but
not limited to, Participant’s name, home address, email address and telephone number, date of birth, social insurance number,
passport number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company,
and details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in
Participant’s favor (“Data”), for the exclusive purpose of implementing, administering and managing the Plan.

Participant
understands that Data will be transferred to a stock plan service provider as may be selected by the Company from time-to-time
(the “Designated Broker”), which is assisting the Company with the implementation, administration and management of
the Plan. Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the
recipient’s country of operation (e.g., the United States) may have different data privacy laws and protections than Participant’s
country. Participant understands that if he or she resides outside the United States, he or she may request a list with the names
and addresses of any potential recipients of the Data by contacting his or her local human resources representative. Participant
authorizes the Company, the Designated Broker and any other possible recipients which may assist the Company (presently or in
the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in
electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan.
Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation
in the Plan. Participant understands that if he or she resides outside the United States, he or she may, at any time, view Data,
request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or
withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative.
Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis. If Participant does
not consent, or if Participant later seeks to revoke his or her consent, his or her status as an eligible service provider under
Article IV of the Plan and career with the Service Recipient will not be adversely affected; the only adverse consequence of refusing
or withdrawing Participant’s consent is that the Company would not be able to grant Participant Options or other equity
awards or administer or maintain such awards. Therefore, Participant understands that refusing or withdrawing his or her consent
may affect Participant’s ability to participate in the Plan. For more information on the consequences of Participant’s
refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources
representative. 

13.

Address
for Notices. Any notice to be given to the Company under the terms of this Award Agreement will be addressed to the Company
at NeuBase Therapeutics, Inc., 700 Technology Drive, Third Floor, Pittsburgh, PA 15219, or at such other address as the Company
may hereafter designate in writing. Any notice to be given to Participant under the terms of this Award Agreement will be addressed
to Participant at the address that he or she most recently provided to the Company.

14.

Electronic
Delivery and Acceptance. The Company may, in its sole and absolute discretion, decide to deliver any documents related to
Options awarded under the Plan or future options that may be awarded under the Plan by electronic means or request Participant’s
consent to participate in the Plan by electronic means. Participant hereby consents to receive such documents by electronic delivery
and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company
or a third party designated by the Company. Participant shall not raise the use of electronic delivery as a defense to the formation
of a contract.

     

     

    

15.

No
Waiver. Either party’s failure to enforce any provision or provisions of this Award Agreement shall not in any way be
construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other
provision of this Award Agreement. The rights granted both parties herein are cumulative and shall not constitute a waiver of
either party’s right to assert all other legal remedies available to it under the circumstances. 

16.

Successors
and Assigns. The Company may assign any of its rights under this Award Agreement to single or multiple assignees, and this
Award Agreement shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer
herein set forth, this Award Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors
and assigns. The rights and obligations of Participant under this Award Agreement may only be assigned with the prior written
consent of the Company. 

17.

Option is Not Transferable. Except by will or under the laws of descent and distribution, this grant and the rights and
privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law
or otherwise) and will not be subject to sale under execution, attachment or similar process. Upon any attempt to transfer, assign,
pledge, hypothecate or otherwise dispose of this grant, or any right or privilege conferred hereby, or upon any attempted sale
under any execution, attachment or similar process, this grant and the rights and privileges conferred hereby immediately will
become null and void. 

18.

Additional
Conditions to Issuance of Common Stock. If at any time the Company will determine, in its sole and absolute discretion, that
the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal
or foreign law, the tax code and related regulations or under the rulings or regulations of the United States Securities and Exchange
Commission or any other governmental regulatory body or the clearance, consent or approval of the United States Securities and
Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the purchase by,
or issuance of Shares, to Participant (or his or her estate) hereunder, such purchase or issuance will not occur unless and until
such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected
or obtained free of any conditions not acceptable to the Company. The Company has sole and absolute discretion in its efforts
to meet the requirements of any such state, federal or foreign law or securities exchange and to obtain any such consent or approval
of any such governmental authority or securities exchange. Subject to the terms of this Award Agreement and the Plan, the Company
shall not be required to issue any certificate or certificates for Shares hereunder prior to the lapse of such reasonable period
of time following the date of exercise of the Option as the Committee may establish from time to time for reasons of administrative
convenience. 

19.

Language.
If Participant has received this Award Agreement or any other document related to the Plan translated into a language other than
English and if the meaning of the translated version is different than the English version, the English version will control.

20.

Interpretation.
The Committee will have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but
not limited to, the determination of whether or not any Shares subject to the Option have vested). All actions taken and all interpretations
and determinations made by the Committee in good faith will be final and binding upon Participant, the Company and all other interested
persons. Neither the Committee nor any person acting on behalf of the Committee will be personally liable for any action, determination
or interpretation made in good faith with respect to the Plan or this Award Agreement. 

21.

Captions. Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction
of this Award Agreement. 

22.

Modifications
to the Agreement. This Award Agreement constitutes the entire understanding of the parties on the subjects covered. Participant
expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations or inducements
other than those contained herein. Modifications to this Award Agreement or the Plan can be made only in an express written contract
executed by a duly authorized officer of the Company. Notwithstanding anything to the contrary in the Plan or this Award
Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole and absolute
discretion and without the consent of Participant, to comply with Code Section 409A or to otherwise avoid imposition of any
additional tax or income recognition under Code Section 409A in connection with this Award of the Option.

     

     

    

23.

Governing
Law and Venue. This Award Agreement will be governed by the laws of the State of Delaware without giving effect to principles
of conflicts of law. For purposes of litigating any dispute that arises under the Option or this Award Agreement, the parties
hereby submit to and consent to the jurisdiction of the State of Delaware, and agree that any such litigation will be conducted
in the Delaware Court of Chancery, or the federal courts for the United States for the District of Delaware, and no other courts,
regardless of where the Option is granted and/or Participant’s services are performed or will be performed. 

24.

Agreement
Severable. In the event that any provision in this Award Agreement will be held invalid or unenforceable, such provision will
be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions
of this Award Agreement. 

25.

Amendment,
Suspension or Termination of the Plan. By accepting this Award, Participant expressly warrants that he or she has received
an Option under the Plan, and has received, read and understood a description of the Plan. Participant understands that the Plan
is discretionary in nature, is established voluntarily by the Company, and may be amended, suspended or terminated by the Company
at any time. 

26.

Entire
Agreement. The Plan is incorporated herein by reference. The Plan and this Award Agreement constitute the entire agreement
of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements
of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to Participant’s
interest except by means of a writing signed by the Company and Participant. 

27.

Country
Addendum. Notwithstanding any provisions in this Award Agreement, the Option shall be subject to any special terms and conditions
set forth in the addendum (if any) to this Award Agreement for Participant’s country (the “Country Addendum”).
Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions
for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions
is necessary or advisable for legal or administrative reasons. The Country Addendum (if any) constitutes part of this Award Agreement.

28.

Insider
Trading Restrictions and Market Abuse Laws. Participant acknowledges that, depending on Participant’s country, Participant
may be subject to insider trading restrictions and/or market abuse laws, which may affect his or her ability to acquire or sell
the Shares or rights to the Shares under the Plan during such times as Participant is considered to have “inside information”
regarding the Company (as defined by the laws in Participant’s country). Any restrictions under these laws or regulations
are separate from and in addition to any restrictions that may be imposed under any applicable Company insider trading policy.
Participant acknowledges that it is Participant’s responsibility to comply with any applicable restrictions, and that Participant
should speak to his or her personal advisor on this matter. 

29.

Foreign
Asset and Account Reporting. Participant’s country may have certain exchange control and/or foreign asset/account reporting
requirements which may affect Participant’s ability to acquire or hold Shares under the Plan or cash received from participating
in the Plan (including from any dividends received or sale proceeds resulting from the sale of Shares) in a brokerage or bank
account outside of Participant’s country. Participant may be required to report such accounts, assets or transactions to
the tax or other authorities in his or her country. Participant acknowledges that it is his or her responsibility to comply with
any applicable regulations, and that Participant should speak to his or her personal advisor on this matter.

30.

Recoupment.
Notwithstanding any other provision herein, the Option and any Shares or other amount or property that may be issued, delivered
or paid in respect of the Option, as well as any consideration that may be received in respect of a sale or other disposition
of any such Shares or property, shall be subject to recoupment under the Plan, in accordance with any clawback policy that the
Company is required to adopt pursuant to the listing standards of any national securities exchange, national market system or
automated quotation system on which the Company’s
securities are listed, quoted or traded or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection
Act of 2010, including but not limited to Section 10D of the Exchange Act, or any other applicable law, as well as any recoupment
or “clawback” policies of the Company that may be in effect from time-to-time.

     

     

    

31.

Limitations
Applicable to Section 16 Persons. Notwithstanding any other provision of the Plan or this Award Agreement, if Participant
is an Officer or Director, then the Plan, the Option and this Award Agreement shall be subject to any additional limitations set
forth in any applicable exemptive rule under Section 16 of the Exchange Act (including any amendment to Rule 16b-3 of the Exchange
Act) that are requirements for the application of such exemptive rule. To the extent permitted by applicable law, this Award Agreement
shall be deemed amended to the extent necessary to conform to such applicable exemptive rule.

32.

Titles;
Headings; Sections. The titles and headings of the sections in this Award Agreement are for convenience of reference only
and, in the event of any conflict, the text of this Award Agreement, rather than such titles or headings, shall control. A reference
to a “Section” in this Award Agreement shall mean a Section of this Award Agreement.

33.

Conversion
to Common Stock-Settled SARs. At any time following the Date of Grant, the Company may convert the Option to a stock-settled
SAR. Upon exercise of a stock-settled SAR, Participant shall receive Shares with a value equal to the excess of (1) the Fair Market
Value of the Shares on the date of exercise over (2) the Exercise Price multiplied by the number of Shares.

[Remainder
of Page Intentionally Left Blank]

 

     

     

    

Exhibit
A

NeuBase
Therapeutics, Inc.

2019
Stock Incentive Plan

Exercise
Notice

NeuBase
Therapeutics, Inc.

700
Technology Drive, Third Floor

Pittsburgh,
PA 15219

Attention:
Chief Financial Officer

1.

Exercise
of Option. Effective as of today,                     ,
        , the undersigned (“Purchaser”) hereby elects
to purchase                  shares (the
“Exercised Shares”) of the Common Stock of NeuBase Therapeutics, Inc. (the “Company”)
under and pursuant to the 2019 Stock Incentive Plan (as may be amended or restated from time to time, the “Plan”)
and the Stock Option Agreement, dated                     
and including the Notice of Grant, the Terms and Conditions of Stock Option Grant, and addendum (if any) and exhibit attached
thereto (the “Award Agreement”). The purchase price for the Exercised Shares will be $            ,
as required by the Award Agreement. 

2.

Delivery
of Payment. Purchaser herewith delivers to the Company the full purchase price of the Exercised Shares and any Tax Obligations
(as defined in Section 7(a) of the Award Agreement) to be paid in connection with the exercise of the Option. 

3.

Representations
of Purchaser. Purchaser acknowledges that Purchaser has received, read and understood the Plan and the Award Agreement and
agrees to abide by and be bound by their terms and conditions. 

4.

Rights
as Stockholder. Until the issuance (as evidenced by the appropriate entry on the books of the Company or of a duly authorized
transfer agent of the Company) of the Exercised Shares, no right to vote or receive dividends or any other rights as a stockholder
will exist with respect to the Exercised Shares subject to the Option, notwithstanding the exercise of the Option. The Exercised
Shares so acquired will be issued to Purchaser as soon as practicable after exercise of the Option. No adjustment will be made
for a dividend or other right for which the record date is prior to the date of issuance, except as provided in Article XI and
Article XII of the Plan. 

5.

Tax
Consultation. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of Purchaser’s purchase
or disposition of the Exercised Shares. Purchaser represents that Purchaser has consulted with any tax consultants Purchaser deems
advisable in connection with the purchase or disposition of the Exercised Shares and that Purchaser is not relying on the Company
for any tax advice. 

6.

Entire
Agreement; Governing Law. The Plan and Award Agreement are incorporated herein by reference. This Exercise Notice, the Plan
and the Award Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede
in their entirety all prior undertakings and agreements of the Company and Purchaser with respect to the subject matter hereof,
and may not be modified adversely to the Purchaser’s interest except by means of a writing signed by the Company and Purchaser.
This exercise notice will be governed by the laws of the State of Delaware without giving effect to principles of conflicts of
law.  

    	 	A-1	 

     

    

 

	 	 	 	 	 
	 

         

        Submitted
        by:
	 	 	 	Accepted
    by:
	 	 	 
	PURCHASER	 	 	 	NEUBASE
    THERAPEUTICS, INC. 
	 	 	 
	 

         
	 	 	 	 

         

	Signature	 	 	 	By
	 	 	 
	 

         
	 	 	 	 

         

	Print
    Name	 	 	 	Print
    Name
	 	 	 
	Address:	 	 

         
	 	 
	 	 	 Title
	 

         
	 	 	 	 
	 	 	 
	 

         
	 	 	 	 
	 	 	 
	 	 	 	 	 

         

	 	 	 	 	Date
    Received

 

    	 	A-2NEUBASE THERAPEUTICS, INC. S-8

Exhibit 4.8

NEUBASE
THERAPEUTICS, INC.

2018
EQUITY INCENTIVE PLAN

STOCK
OPTION AGREEMENT

Unless
otherwise defined herein, the terms defined in the 2018 Equity Incentive Plan (the “Plan”) shall have the same defined
meanings in this Stock Option Agreement (the “Option Agreement”). 

I.

NOTICE
OF STOCK OPTION GRANT

	 	Name:	«Name»
	 	 	 
		Address:	«Address»

                                         «City_State_Zip»

The
undersigned Participant has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions
of the Plan and this Option Agreement, as follows:

	 	Date
    of Grant:	«Grant_Date»
	 	Vesting
    Commencement Date:	«Vest_Date»
	 	Exercise
    Price per Share:	$
    «Price_Per_Share»
	 	Total
    Number of Shares Granted:	«Shares»
	 	Total
    Exercise Price:	$
    «Total_Price»
	 	Type
    of Option:	«ISO»	Incentive
    Stock Option
	 	 	«NSO»	Nonstatutory
    Stock Option
	 	Term/Expiration
    Date:	«Expire_Date»

Vesting
Schedule:

This
Option shall be exercisable, in whole or in part, according to the following vesting schedule:

[Twenty-five
percent (25%) of the Shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date,
and one forty-eighth (1/48th) of the Shares subject to the Option shall vest each month thereafter on the same day
of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to
Participant continuing to be a Service Provider through each such date.]

     

     

    

Termination
Period:

This
Option shall be exercisable for [three (3) months] after Participant ceases to be a Service Provider, unless such termination
is due to Participant’s death or Disability, in which case this Option shall be exercisable for [twelve (12) months] after
Participant ceases to be a Service Provider. Notwithstanding the foregoing sentence, in no event may this Option be exercised
after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 13
of the Plan. 

II.

AGREEMENT

 

1.

Grant
of Option. The Administrator of the Company hereby grants to the Participant named in the Notice of Stock Option Grant in
Part I of this Option Agreement (“Participant”), an option (the “Option”) to purchase the number of Shares
set forth in the Notice of Stock Option Grant, at the exercise price per Share set forth in the Notice of Stock Option Grant (the
“Exercise Price”), and subject to the terms and conditions of the Plan, which is incorporated herein by reference.
Subject to Section 18 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option
Agreement, the terms and conditions of the Plan shall prevail.

If
designated in the Notice of Stock Option Grant as an Incentive Stock Option (“ISO”), this Option is intended to qualify
as an Incentive Stock Option as defined in Section 422 of the Code. Nevertheless, to the extent that it exceeds the $100,000
rule of Code Section 422(d), this Option shall be treated as a Nonstatutory Stock Option (“NSO”). Further, if
for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such
Option (or portion thereof) shall be regarded as a NSO granted under the Plan. In no event shall the Administrator, the Company
or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other
person) due to the failure of the Option to qualify for any reason as an ISO.

2.

Exercise
of Option.

(a)

Right
to Exercise. This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice
of Stock Option Grant and with the applicable provisions of the Plan and this Option Agreement.

(b)

Method
of Exercise. This Option shall be exercisable by delivery of an exercise notice in the form attached as Exhibit A
(the “Exercise Notice”) or in a manner and pursuant to such procedures as the Administrator may determine, which
shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the
“Exercised Shares”), and such other representations and agreements as may be required by the Company. The Exercise
Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable
tax withholding. This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice
accompanied by the aggregate Exercise Price, together with any applicable tax withholding.

No
Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws.
Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Participant on the date on which
the Option is exercised with respect to such Shares.

     

     

    

3.

Participant’s
Representations. In the event the Shares have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), at the time this Option is exercised, Participant shall, if required by the Company, concurrently with the exercise
of all or any portion of this Option, deliver to the Company his or her Investment Representation Statement in the form attached
hereto as Exhibit B.

4.

Lock-Up
Period. Participant hereby agrees that Participant shall not offer, pledge, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer
or dispose of, directly or indirectly, any Common Stock (or other securities) of the Company or enter into any swap, hedging or
other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any Common
Stock (or other securities) of the Company held by Participant (other than those included in the registration) for a period specified
by the representative of the underwriters of Common Stock (or other securities) of the Company not to exceed one hundred and eighty
(180) days following the effective date of any registration statement of the Company filed under the Securities Act (or such other
period as may be requested by the Company or the underwriters to accommodate regulatory restrictions on (i) the publication
or other distribution of research reports and (ii) analyst recommendations and opinions, including, but not limited to, the
restrictions contained in NYSE Rule 472(f)(4), or any successor provisions or amendments thereto).

Participant
agrees to execute and deliver such other agreements as may be reasonably requested by the Company or the underwriter which
are consistent with the foregoing or which are necessary to give further effect thereto. In addition, if requested by the
Company or the representative of the underwriters of Common Stock (or other securities) of the Company, Participant shall
provide, within ten (10) days of such request, such information as may be required by the Company or such representative in
connection with the completion of any public offering of the Company’s securities pursuant to a registration
statement filed under the Securities Act. The obligations described in this Section 4 shall not apply to a registration
relating solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or
a registration relating solely to a Commission Rule 145 transaction on Form S-4 or similar forms that may be promulgated in
the future. The Company may impose stop-transfer instructions with respect to the shares of Common Stock (or other
securities) subject to the foregoing restriction until the end of said one hundred and eighty (180) day (or other) period.
Participant agrees that any transferee of the Option or shares acquired pursuant to the Option shall be bound by this Section
4.

 

5.

Method
of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election
of the Participant:

(a)

cash;

(b)

check;

(c)

consideration
received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or

(d)

surrender
of other Shares which (i) shall be valued at its Fair Market Value on the date of exercise, and (ii) must be owned free and clear
of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator,
shall not result in any adverse accounting consequences to the Company.

 

     

     

    

 

6.

Restrictions
on Exercise. This Option may not be exercised until such time as the Plan has been approved by the stockholders of the Company,
or if the issuance of such Shares upon such exercise or the method of payment of consideration for such shares would constitute
a violation of any Applicable Law.

7.

Non-Transferability
of Option.

(a)

This
Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised
during the lifetime of Participant only by Participant. The terms of the Plan and this Option Agreement shall be binding upon
the executors, administrators, heirs, successors and assigns of Participant.

(b)

Further,
until the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, or after the Administrator
determines that it is, will, or may no longer be relying upon the exemption from registration of Options under the Exchange Act
as set forth in Rule 12h-1(f) promulgated under the Exchange Act (the “Reliance End Date”), Participant shall not
transfer this Option or, prior to exercise, the Shares subject to this Option, in any manner other than (i) to persons who are
“family members” (as defined in Rule 701(c)(3) of the Securities Act) through gifts or domestic relations orders,
or (ii) to an executor or guardian of Participant upon the death or disability of Participant. Until the Reliance End Date, the
Options and, prior to exercise, the Shares subject to this Option, may not be pledged, hypothecated or otherwise transferred or
disposed of, including by entering into any short position, any “put equivalent position” or any “call equivalent
position” (as defined in Rule 16a-1(h) and Rule 16a-1(b) of the Exchange Act, respectively), other than as permitted in
clauses (i) and (ii) of this paragraph.

8.

Term
of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised
during such term only in accordance with the Plan and the terms of this Option Agreement.

9.

Tax
Obligations.

(a)

Tax
Withholding. Participant agrees to make appropriate arrangements with the Company (or the Parent or Subsidiary employing
or retaining Participant) for the satisfaction of all Federal, state, local and foreign income and employment tax withholding
requirements applicable to the Option exercise. Participant acknowledges and agrees that the Company may refuse to
honor the exercise and refuse to deliver the Shares if such withholding amounts are not delivered at the time of
exercise.

(b)

Notice
of Disqualifying Disposition of ISO Shares. If the Option granted to Participant herein is an ISO, and if Participant sells
or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years
after the Date of Grant, or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the
Company in writing of such disposition. Participant agrees that Participant may be subject to income tax withholding by the Company
on the compensation income recognized by Participant.

 

     

     

    

(c)

Code
Section 409A. Under Code Section 409A, an Option that vests after December 31, 2004 (or that vested on or prior to such date
but which was materially modified after October 3, 2004) that was granted with a per Share exercise price that is determined by
the Internal Revenue Service (the “IRS”) to be less than the Fair Market Value of a Share on the date of grant (a
“discount option”) may be considered “deferred compensation.” An Option that is a “discount option”
may result in (i) income recognition by Participant prior to the exercise of the Option, (ii) an additional twenty percent (20%)
federal income tax, and (iii) potential penalty and interest charges. The “discount option” may also result in additional
state income, penalty and interest tax to the Participant. Participant acknowledges that the Company cannot and has not guaranteed
that the IRS will agree that the per Share exercise price of this Option equals or exceeds the Fair Market Value of a Share on
the date of grant in a later examination. Participant agrees that if the IRS determines that the Option was granted with a per
Share exercise price that was less than the Fair Market Value of a Share on the date of grant, Participant shall be solely responsible
for Participant’s costs related to such a determination.

10.

Entire
Agreement; Governing Law. The Plan is incorporated herein by reference. The Plan and this Option Agreement constitute the
entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings
and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to
the Participant’s interest except by means of a writing signed by the Company and Participant. This Option Agreement is
governed by the internal substantive laws but not the choice of law rules of Delaware.

11.

No
Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE
HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR
RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT
FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH
HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR
ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT
OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME,
WITH OR WITHOUT CAUSE.

 

     

     

    

 

Participant
acknowledges receipt of a copy of the Plan and represents that he or she is familiar with the terms and provisions thereof, and
hereby accepts this Option subject to all of the terms and provisions thereof. Participant has reviewed the Plan and this Option
in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option and fully understands
all provisions of the Option. Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations
of the Administrator upon any questions arising under the Plan or this Option. Participant further agrees to notify the Company
upon any change in the residence address indicated below.

 

	PARTICIPANT	 	NEUBASE
        THERAPEUTICS, INC.
	 	 	 
	Signature	 	By
	 	 	 
	«Name»	 	 
	Print Name	 	Print Name
	 	 	 
	«Address»	 	 
	 	 	Title
	«City_State_Zip»	 	 
	Residence
        Address	 	 

     

     

    

EXHIBIT
A

2018
EQUITY INCENTIVE PLAN

EXERCISE
NOTICE

 

NeuBase
Therapeutics, Inc.

2730
Sidney Street

Suite
300

Pittsburgh,
PA 15203

Attention:
President

 

1.

Exercise
of Option. Effective as of today, ________________, ____, the undersigned (“Participant”) hereby elects to exercise
Participant’s option (the “Option”) to purchase ________________ shares of the Common Stock (the “Shares”)
of NeuBase Therapeutics, Inc. (the “Company”) under and pursuant to the 2018 Equity Incentive Plan (the “Plan”)
and the Stock Option Agreement dated ______________, _____ (the “Option Agreement”).

2.

Delivery
of Payment. Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option
Agreement, and any and all withholding taxes due in connection with the exercise of the Option.

3.

Representations
of Participant. Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement
and agrees to abide by and be bound by their terms and conditions.

4.

Rights
as Stockholder. Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of
a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall
exist with respect to the Common Stock subject to an Award, notwithstanding the exercise of the Option. The Shares shall be issued
to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement. No adjustment shall
be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in Section 13
of the Plan.

5.

Company’s
Right of First Refusal. Before any Shares held by Participant or any transferee (either being sometimes referred to herein
as the “Holder”) may be sold or otherwise transferred (including transfer by gift or operation of law), the Company
or its assignee(s) shall have a right of first refusal to purchase the Shares on the terms and conditions set forth in this Section 5
(the “Right of First Refusal”).

(a)

Notice
of Proposed Transfer. The Holder of the Shares shall deliver to the Company a written notice (the “Notice”) stating:
(i) the Holder’s bona fide intention to sell or otherwise transfer such Shares; (ii) the name of each proposed
purchaser or other transferee (“Proposed Transferee”); (iii) the number of Shares to be transferred to each Proposed
Transferee; and (iv) the bona fide cash price or other consideration for which the Holder proposes to transfer the Shares
(the “Offered Price”), and the Holder shall offer the Shares at the Offered Price to the Company or its assignee(s).

 

     

     

    

 

(b)

Exercise
of Right of First Refusal. At any time within thirty (30) days after receipt of the Notice, the Company and/or its assignee(s)
may, by giving written notice to the Holder, elect to purchase all, but not less than all, of the Shares proposed to be transferred
to any one or more of the Proposed Transferees, at the purchase price determined in accordance with subsection (c) below.

(c)

Purchase
Price. The purchase price (“Purchase Price”) for the Shares purchased by the Company or its assignee(s) under
this Section 5 shall be the Offered Price. If the Offered Price includes consideration other than cash, the cash equivalent
value of the non-cash consideration shall be determined by the Board of Directors of the Company in good faith.

(d)

Payment.
Payment of the Purchase Price shall be made, at the option of the Company or its assignee(s), in cash (by check), by
cancellation of all or a portion of any outstanding indebtedness of the Holder to the Company (or, in the case of
repurchase by an assignee, to the assignee), or by any combination thereof within thirty (30) days after receipt of the
Notice or in the manner and at the times set forth in the Notice.

(e)

Holder’s
Right to Transfer. If all of the Shares proposed in the Notice to be transferred to a given Proposed Transferee are not purchased
by the Company and/or its assignee(s) as provided in this Section 5, then the Holder may sell or otherwise transfer such
Shares to that Proposed Transferee at the Offered Price or at a higher price, provided that such sale or other transfer
is consummated within one hundred and twenty (120) days after the date of the Notice, that any such sale or other transfer is
effected in accordance with any applicable securities laws and that the Proposed Transferee agrees in writing that the provisions
of this Section 5 shall continue to apply to the Shares in the hands of such Proposed Transferee. If the Shares described
in the Notice are not transferred to the Proposed Transferee within such period, a new Notice shall be given to the Company, and
the Company and/or its assignees shall again be offered the Right of First Refusal before any Shares held by the Holder may be
sold or otherwise transferred.

(f)

Exception
for Certain Family Transfers. Anything to the contrary contained in this Section 5 notwithstanding, the transfer of any
or all of the Shares during the Participant’s lifetime or on the Participant’s death by will or intestacy to the Participant’s
immediate family or a trust for the benefit of the Participant’s immediate family shall be exempt from the provisions of
this Section 5. “Immediate Family” as used herein shall mean spouse, lineal descendant or antecedent, father,
mother, brother or sister. In such case, the transferee or other recipient shall receive and hold the Shares so transferred subject
to the provisions of this Section 5, and there shall be no further transfer of such Shares except in accordance with the
terms of this Section 5.

(g)

Termination
of Right of First Refusal. The Right of First Refusal shall terminate as to any Shares upon the earlier of (i) the first sale
of Common Stock of the Company to the general public, or (ii) a Change in Control in which the successor corporation has equity
securities that are publicly traded.

 

     

     

    

6.

Tax
Consultation. Participant understands that Participant may suffer adverse tax consequences as a result of Participant’s
purchase or disposition of the Shares. Participant represents that Participant has consulted with any tax consultants Participant
deems advisable in connection with the purchase or disposition of the Shares and that Participant is not relying on the Company
for any tax advice.

7.

Restrictive
Legends and Stop-Transfer Orders.

(a)

Legends.
Participant understands and agrees that the Company shall cause the legends set forth below or legends substantially equivalent
thereto, to be placed upon any certificate(s) evidencing ownership of the Shares together with any other legends that may be required
by the Company or by state or federal securities laws:

THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE
OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR, IN THE OPINION OF
COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS IN COMPLIANCE
THEREWITH.

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AND A RIGHT OF FIRST REFUSAL HELD BY THE
ISSUER OR ITS ASSIGNEE(S) AS SET FORTH IN THE EXERCISE NOTICE BETWEEN THE ISSUER AND THE ORIGINAL HOLDER OF THESE SHARES, A COPY
OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE ISSUER. SUCH TRANSFER RESTRICTIONS AND RIGHT OF FIRST REFUSAL ARE BINDING
ON TRANSFEREES OF THESE SHARES.

THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO RESTRICTIONS ON TRANSFER FOR A PERIOD OF TIME FOLLOWING THE EFFECTIVE
DATE OF THE UNDERWRITTEN PUBLIC OFFERING OF THE COMPANY’S SECURITIES SET FORTH IN AN AGREEMENT BETWEEN THE ISSUER AND
THE ORIGINAL HOLDER OF THESE SHARES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF BY THE HOLDER PRIOR TO THE EXPIRATION
OF SUCH PERIOD WITHOUT THE CONSENT OF THE COMPANY OR THE MANAGING UNDERWRITER.

(b)

Stop-Transfer
Notices. Participant agrees that, in order to ensure compliance with the restrictions referred to herein, the Company may
issue appropriate “stop transfer” instructions to its transfer agent, if any, and that, if the Company transfers its
own securities, it may make appropriate notations to the same effect in its own records.

(c)

Refusal
to Transfer. The Company shall not be required (i) to transfer on its books any Shares that have been sold or otherwise
transferred in violation of any of the provisions of this Exercise Notice or (ii) to treat as owner of such Shares or to
accord the right to vote or pay dividends to any purchaser or other transferee to whom such Shares shall have been so transferred.

 

     

     

    

8.

Successors
and Assigns. The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this
Exercise Notice shall inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer
herein set forth, this Exercise Notice shall be binding upon Participant and his or her heirs, executors, administrators, successors
and assigns.

9.

Interpretation.
Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith
to the Administrator, which shall review such dispute at its next regular meeting. The resolution of such a dispute by the Administrator
shall be final and binding on all parties.

10.

Governing
Law; Severability. This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of
Delaware. In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable
or void, this Exercise Notice shall continue in full force and effect.

11.

Entire
Agreement. The Plan and Option Agreement are incorporated herein by reference. This Exercise Notice, the Plan, the Option
Agreement and the Investment Representation Statement constitute the entire agreement of the parties with respect to the subject
matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect
to the subject matter hereof, and may not be modified adversely to the Participant’s interest except by means of a writing
signed by the Company and Participant. 

 

	Submitted
        by:	 	Accepted
        by:
	 	 	 
	PARTICIPANT	 	NEUBASE
        THERAPEUTICS, INC.
	 	 	 
	Signature	 	By
	 	 	 
	«Name»	 	 
	Print Name	 	Print Name
	 	 	 
	 	 	 
	 	 	Title
	Address:	 	 
	 	 	Address:
	 	 	 
	«Address»	 	2730
        Sidney Street
	 	 	Suite
        300
	«City_State_Zip»	 	Pittsburgh,
        PA 15203
	 	 	 
	 	 	Date Received

     

     

    

EXHIBIT
B

INVESTMENT
REPRESENTATION STATEMENT

 

	PARTICIPANT:	«Name»
	 	 
	COMPANY:	NEUBASE
THERAPEUTICS, INC.
	 	 
	SECURITY:	COMMON
STOCK
	 	 
	AMOUNT:	«Shares»
	 	 
	DATE:	 

In
connection with the purchase of the above-listed Securities, the undersigned Participant represents to the Company the following:

 

(a)

Participant
is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company
to reach an informed and knowledgeable decision to acquire the Securities. Participant is acquiring these Securities for investment
for Participant’s own account only and not with a view to, or for resale in connection with, any “distribution”
thereof within the meaning of the Securities Act of 1933, as amended (the “Securities Act”).

(b)

Participant
acknowledges and understands that the Securities constitute “restricted securities” under the Securities Act and have
not been registered under the Securities Act in reliance upon a specific exemption therefrom, which exemption depends upon, among
other things, the bona fide nature of Participant’s investment intent as expressed herein. In this connection, Participant
understands that, in the view of the Securities and Exchange Commission, the statutory basis for such exemption may be unavailable
if Participant’s representation was predicated solely upon a present intention to hold these Securities for the minimum
capital gains period specified under tax statutes, for a deferred sale, for or until an increase or decrease in the market price
of the Securities, or for a period of one (1) year or any other fixed period in the future. Participant further understands that
the Securities must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from
such registration is available. Participant further acknowledges and understands that the Company is under no obligation to register
the Securities. Participant understands that the certificate evidencing the Securities shall be imprinted with any legend required
under applicable state securities laws.

(c)

Participant
is familiar with the provisions of Rule 701 and Rule 144, each promulgated under the Securities Act, which, in substance,
permit limited public resale of “restricted securities” acquired, directly or indirectly from the issuer thereof,
in a non-public offering subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies
under Rule 701 at the time of the grant of the Option to Participant, the exercise shall be exempt from registration under
the Securities Act. In the event the Company becomes subject to the reporting requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, ninety (90) days thereafter (or such longer period as any market stand-off agreement may
require) the Securities exempt under Rule 701 may be resold, subject to the satisfaction of the applicable conditions specified
by Rule 144, including in the case of affiliates (1) the availability of certain public information about the Company,
(2) the amount of Securities being sold during any three (3) month period not exceeding specified limitations, (3) the
resale being made in an unsolicited “broker’s transaction”, transactions directly with a “market maker”
or “riskless principal transactions” (as those terms are defined under the Securities Exchange Act of 1934) and (4) the
timely filing of a Form 144, if applicable.

 

     

     

    

In
the event that the Company does not qualify under Rule 701 at the time of grant of the Option, then the Securities may be
resold in certain limited circumstances subject to the provisions of Rule 144, which may require (i) the availability
of current public information about the Company; (ii) the resale to occur more than a specified period after the purchase
and full payment (within the meaning of Rule 144) for the Securities; and (iii) in the case of the sale of Securities
by an affiliate, the satisfaction of the conditions set forth in sections (2), (3) and (4) of the paragraph immediately above.

(d)

Participant
further understands that in the event all of the applicable requirements of Rule 701 or 144 are not satisfied, registration
under the Securities Act, compliance with Regulation A, or some other registration exemption shall be required; and that, notwithstanding
the fact that Rules 144 and 701 are not exclusive, the Staff of the Securities and Exchange Commission has expressed its
opinion that persons proposing to sell private placement securities other than in a registered offering and otherwise than pursuant
to Rules 144 or 701 shall have a substantial burden of proof in establishing that an exemption from registration is available
for such offers or sales, and that such persons and their respective brokers who participate in such transactions do so at their
own risk. Participant understands that no assurances can be given that any such other registration exemption shall be available
in such event.

 

	 	PARTICIPANT
	 	 
	 	 
	 	Signature
	 	 
	 	«Name»
	 	Print Name
	 	 
	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]